Passer au contenu principal
Centre intégré universitaire de santé
et de services sociaux de l'Est-de-l'Île-de-Montréal

Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal

Josée Hébert

Hébert, Josée

Full professor


Université de Montréal

Research Axes


Contact information

Phone: 514-252-3404


  • Majid Ameziane
  • François Béliveau
  • Vanessa Gagnon
  • Sandrine Lacoste
  • Sylvie Lavallée
  • Corinne Linarès
  • Suzanne Power
  • Claude Rondeau
  • Marie Claude Sasseville
  • Ginette Trottier

A hematologist and cytogeneticist, Dr. Josée Hébert is the co-founder and director of the Quebec Leukemia Cell Bank, which is based at the Centre de recherche de l'Hôpital Maisonneuve-Rosemont. She is involved in clinical research in the leukemia program of the Department of Hematology and Oncology and heads the Clinical Cytogenetics Laboratory at the HMR. She is also a full professor in the Faculty of Medicine at Université de Montréal and holds the Industrielle-Alliance Research Chair in Leukemia at Université de Montréal.

Dr. Hébert has developed extensive expertise in leukemia and cancer cytogenetics. She is a co-principal investigator with Leucegene at the IRIC-HMR, a multidisciplinary team that does translational leukemia research. The goal of this group is to identify novel therapeutic targets and develop new therapies for acute leukemia. Dr. Hébert is also a member of the Executive Committee of the Cancer Research Network of the Fonds de la recherche du Québec – Santé.

Research Unit

Quebec Leukemia Cell Bank – Genetics of leukemia

Research interests

The goals of the Leucegene group are to :

  • Improve the prognostic stratification of acute myeloid leukemia (AML) and discover new predictive markers to provide AML patients with personalized treatment to improve their survival.
  • Develop new effective therapies for this type of leukemia.

The experimental approaches that we use include complete transcriptome and genome sequencing, chemogenomics and proteomics. For this project, the team sequenced 700 AML samples from the Quebec Leukemia Cell Bank (QLCB) that have good biological and clinical characterization. New gene mutations and signatures as well as a new prognostic marker have been discovered for each of the major AML genetic subgroups. Since 2018, we have been analyzing the genetic profiles of rare AML subgroups as well as the surfaceome of about 100 leukemic samples. We have also been working to identify predictive biomarkers for specific AML therapies. We conducted high throughput chemical screening using 10,000 chemical compounds and 56 genetically diverse AML samples that will allow us to identify novel therapeutic targets and novel chemical compounds that are effective for this cancer.

Quebec Leukemia Cell Bank (QLCB)

Since 2004, the QLCB has contributed to over 110 research projects and many scientific publications in hematological cancers. The QLCB's cytogenetics platform provides standard and molecular cytogenetic analysis and spectral karyotyping (SKY) services for cancer researchers. Thanks to its unique expertise, our team has worked on many research projects in the field of leukemia genetics and DNA repair.

  • Bisaillon R, Moison C, Thiollier C, Krosl J, Bordeleau ME, Lehnertz B, Lavallée VP, MacRae T, Mayotte N, Labelle C, Boucher G, Spinella JF, Boivin I, D’Angelo G, Lavallée S, Marinier A, Lemieux S, Hébert J, Sauvageau G. Genetic characterization of ABT-199 sensitivity in human AML. Leukemia. 2019 Jul 12;. doi: 10.1038/s41375-019-0485-x. [Epub ahead of print] PubMed PMID: 31300747.
    More detail
  • Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella JF, Corneau S, Mayotte N, Girard S, Frechette M, Blouin-Chagnon V, Leveillé K, Boivin I, MacRae T, Krosl J, Thiollier C, Lavallée VP, Kanshin E, Bertomeu T, Coulombe-Huntington J, St-Denis C, Bordeleau ME, Boucher G, Roux PP, Lemieux S, Tyers M, Thibault P, Hébert J, Marinier A, Sauvageau G. Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. Cancer Cell. 2019 Jul 8;36(1):84-99.e8. doi: 10.1016/j.ccell.2019.06.003. PubMed PMID: 31287994.
    More detail
  • Marquis M, Beaubois C, Lavallée VP, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, Hébert J. High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6. PubMed PMID: 30061630.
    More detail
  • Lavallée VP, Chagraoui J, MacRae T, Marquis M, Bonnefoy A, Krosl J, Lemieux S, Marinier A, Pabst C, Rivard GÉ, Hébert J*, Sauvageau G*. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. Leukemia. 2018 Feb 23. doi: 10.1038/s41375-018-0069-1. [Epub ahead of print]. *: co-corresponding authors.
    More detail
  • Simon L, Lavallée VP, Bordeleau ME, Krosl J , Baccelli I, Boucher G , Lehnertz B, Chagraoui J, MacRae T, Ruel R , Chantigny YA , Lemieux S, Marinier A, Hébert J*, Sauvageau G*. Chemogenomic landscape of RUNX1-mutated AML reveals importance of RUNX1 allele dosage in genetics and glucocorticoid sensitivity. Clin Cancer Res. 2017 Nov 15;23(22):6969-6981.
    More detail
  • Maiga A, Lemieux S, Pabst C, Lavallée VP, Bouvier M, Sauvageau G, Hébert J. Transcriptome analysis of G Protein-Coupled Receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets. Blood Cancer J. 2016 Jun3;6(6):e431.
    More detail
  • Lavallée VP, Krosl J, Lemieux S, Boucher G, Gendron P, Pabst C, Boivin I, Marinier A, Guidos CJ, Meloche S, Hébert J*, Sauvageau G*. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. Blood. 2016 Jun 16;127(24):3054-61.
    More detail
  • Lavallée VP, Lemieux S, Boucher G, Gendron P, Boivin I, Armstrong RN, Sauvageau G, Hébert J. RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. Blood. 2016 May 19;127(20):2498-501.
    More detail
  • Lavallée VP, Baccelli I, Krosl J, Wilhelm B, Barabe F, Gendron P, Boucher G, Lemieux S, Marinier A, Meloche S, Hébert J*, Sauvageau G*. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat. Genet. 2015;47(9):1030-7.
    More detail
  • Lavallée VP, Gendron P, Lemieux S, D'Angelo G, Hébert J*, Sauvageau G*. EVI1-Rearranged Acute Myeloid Leukemias Are Characterized by Distinct Molecular Alterations. Blood. 2015;125(1):140-3.
    More detail


  • INSERM U301 and Molecular Hematology Laboratory: Research fellowship in the genetics of leukemia

    Hôpital Saint-Louis, Paris

  • Hematology, FRCPC

    Université de Montréal

  • Internal medicine

    Université de Montréal

  • Doctor of Medicine

    Université de Montréal


  • 2009 Industrielle Alliance Research Chair in Leukemia – Until 2024  (Université de Montréal)